Development of an adenoviral vector with robust expression driven by p53

Area of Science:

• Molecular Biology
• Gene Therapy
• Oncology

Background:

• The tumor suppressor protein p53 plays a critical role in cellular responses to stress.
• Developing targeted gene delivery systems that respond to p53 activity is crucial for cancer research and therapy.

Purpose of the Study:

• To engineer a novel adenoviral vector with p53-inducible transgene expression.
• To evaluate the efficacy and specificity of this vector in prostate cancer cell lines.

Main Methods:

• Construction of a synthetic p53-responsive promoter (PGTxbeta) linked to an adenoviral vector (AdPG).
• Assays using plasmid and adenoviral vectors to assess p53-driven expression in various prostate cancer cell lines (LNCaP, DU-145, PC3).
• Evaluation of AdPG as a sensor for p53 activity in response to chemotherapeutic agents.

Main Results:

• The synthetic PGTxbeta promoter demonstrated tightly p53-controlled and enhanced expression compared to the CMV promoter.
• AdPG successfully achieved p53-responsive transgene expression in prostate cancer cells with wild-type, mutant, or engineered p53.
• AdPG effectively monitored p53 activity in LNCaP cells treated with chemotherapy.

Conclusions:

• A novel adenoviral vector (AdPG) with p53-responsive gene expression has been successfully developed.
• This vector shows promise as a tool for monitoring p53 activity and for potential combination therapies in cancer treatment.
• AdPG offers a new platform for integrating genetic and pharmacologic approaches in cancer treatment strategies.